“One of the nice things that’s happened over time is that there’s been development of a whole series of drugs addressing auto-immune diseases. And so there is a drug based upon an interleukin 23 alpha gene that is available for rheumatoid arthritis, and it seems to be doing well,” Rich said. “Now before, the gene for rheumatoid arthritis – that is one of many genes, rheumatoid arthritis – but this gene was not a gene for type 1 diabetes. But with our study, we now find that it is. And so suddenly, we have drugs for other auto-immune diseases that are on the market, that are being used, that have not been used before for type 1 diabetes. Now, this points to drugs that might be able to be used.” - Dr. Stephen Rich, one of the study’s researchers, serves as the director of the Center for Public Health Genomics within the University of Virginia’s School of Medicine. He also serves as a professor of Public Health Sciences and a professor of Biochemistry, Microgenetics and Biology.